

Second Preliminary Amendment

In the claims:

Please cancel claims 1-5, 8-14, 16 and 19-25 and add new claims 86-103. This listing of the claims replaces all prior versions and listings of claims in the applications.

1-85. (Canceled)

86. (New): An isolated antibody, or antigen binding fragment thereof, that specifically binds to a polypeptide selected from the group consisting of:

a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO:415 or SEQ ID NO:416;

b) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to the nucleotide sequence of the DNA insert of clone EpT294, which was deposited with ATCC as Accession Number 207220;

c) a polypeptide which is at least 90% identical to the amino acid sequence of SEQ ID NO:417;

d) a polypeptide which is at least 90% identical to residues 15-423 of the amino acid sequence of SEQ ID NO:417; and

e) a polypeptide which is at least 90% identical to residues 34-254 of the amino acid sequence of SEQ ID NO:417;

wherein the polypeptide exhibits a lipase activity.

87. (New): The antibody, or antigen binding fragment thereof, of claim 86, wherein said antibody is selected from the group consisting of:

i) a monoclonal antibody;

ii) a polyclonal antibody;

iii) a humanized antibody;

iv) a chimeric antibody; and

v) a human antibody.

88. (New): The antibody, or antigen binding fragment thereof of claim 86, wherein said antigen binding fragment is a F(ab) fragment or a F(ab')₂ fragment.

89. (New): The antibody, or antigen binding fragment thereof of claim 86, wherein said antibody binds to amino acid residues 15-423 of SEQ ID NO:417.

90. (New): The antibody, or antigen binding fragment thereof of claim 86, wherein said antibody binds to amino acid residues 34-254 of SEQ ID NO:417.

91. (New): The antibody, or antigen binding fragment thereof of claim 86, wherein said antibody is detectably labeled.

92. (New): The antibody, or antigen binding fragment thereof of claim 91, wherein the detectable label is selected from the group consisting of:

- a) enzymes;
- b) prosthetic groups;
- c) fluorescent materials;
- d) luminescent materials;
- e) bioluminescent materials; and
- f) radioactive materials.

93. (New): The antibody, or antigen binding fragment thereof of claim 86, wherein said antibody is conjugated to a therapeutic moiety.

94. (New): The antibody, or antigen binding fragment thereof of claim 93, wherein the therapeutic moiety is selected from the group consisting of:

- a) a cytotoxin;
- b) a therapeutic agent; and
- c) a radioactive agent.

95. (New): An isolated antibody, or antigen binding fragment thereof, that specifically binds to a polypeptide selected from the group consisting of:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:417;
- b) a polypeptide comprising the amino acid sequence of SEQ ID NO:419;
- c) the polypeptide encoded by the nucleic acid molecule of SEQ ID NO:415 or 416; and
- d) the polypeptide encoded by the nucleotide sequence of the DNA insert of clone EpT294, which was deposited with ATCC as Accession Number 207220.

96. (New): The antibody, or antigen binding fragment thereof of claim 95, wherein said antibody is selected from the group consisting of:

- i) a monoclonal antibody;
- ii) a polyclonal antibody;
- iii) a humanized antibody;
- iv) a chimeric antibody; and
- v) a human antibody.

97. (New): The antibody, or antigen binding fragment thereof of claim 95, wherein said antigen binding fragment is a F(ab) fragment or a F(ab')₂ fragment.

98. (New): The antibody, or antigen binding fragment thereof of claim 95, wherein said antibody binds to amino acid residues 15-423 of SEQ ID NO:417.

99. (New): The antibody, or antigen binding fragment thereof of claim 95, wherein said antibody binds to amino acid residues 34 to 254 of SEQ ID NO:417.

100. (New): The antibody, or antigen binding fragment thereof of claim 95, wherein said antibody is detectably labeled.

101. (New): The antibody, or antigen binding fragment thereof of claim 100, wherein the detectable label is selected from the group consisting of:

- a) enzymes;
- b) prosthetic groups;

- c) fluorescent materials;
- d) luminescent materials;
- e) bioluminescent materials; and
- f) radioactive materials.

102. (New): The antibody, or antigen binding fragment thereof of claim 95, wherein said antibody is conjugated to a therapeutic moiety.

103. (New): The antibody, or antigen binding fragment thereof of claim 102, wherein the therapeutic moiety is selected from the group consisting of:

- a) a cytotoxin;
- b) a therapeutic agent; and
- c) a radioactive agent.